Compare Citius Pharmaceuticals Inc (CTXR) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs HSBC Holdings plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while HSBC Holdings plc trades at $93.02 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 22901.6× Citius Pharmaceuticals Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and HSBC Holdings plc for 36 Days on average.
| CTXR | HSBC | |
|---|---|---|
Market Cap | $13.62M | $311.92B |
Volume | 132,438 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $1.82 | $107.86 |
52-Week Low | $0.48 | $65.67 |
Typical Hold Time | 17 Days | 36 Days |
Enterprise Value | $3.79M | $222.19B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
